Sberbank and R-Pharm Group have announced the signing of an agreement to jointly purchase a stake in Eapteka and to invest in its development, the parties informed.
Under the terms of the transaction, Sberbank and R-Pharm Group will each acquire 45% of the company's shares upon receipt of the required antitrust approvals, while Anton Buzdalin, founder and CEO of Eapteca, will retain a 10% stake.
The company will operate under the Sber Eapteka brand. The transaction is expected to close in the fourth quarter of 2020.
Eapteka founded in 2011 cis currently one of the largest online pharmacies in Russia, operating in more than 70 cities of Russia, including Moscow, St. Petersburg, Kazan, Nizhny Novgorod, Sochi, Krasnoyarsk, Yekaterinburg, Rostov-on-Don, Perm and Irkutsk.
Sberbank of Russia (tax number: 7707083893) is the largest bank in Russia, Central and Eastern Europe. The Bank is the principal lender to the Russian economy and has the highest share in the market of deposits. The bank's authorized capital is RUB 67.76 billion. It consists of 21,586,948 thousand common shares and 1 billion preferred shares with a face value of 3 rubles each. The Russian Federation represented by the Ministry of Finance owns 52.32% of Sberbank's total voting shares.
